The potential role in HIFU telehealth in the management of fibroid and adenomyosis after COVID-19 pandemic

In: World Journal of Advanced Research and Reviews 9(2) 027-031 · 2021 · doi:10.5281/zenodo.4625538 · W4287322264
article OA: green CC0
AI-generated summary by qwen3.7-flash, 2026-09-07

This paper illustrates how telehealth can modify high-intensity focused ultrasound training and patient management for fibroids and adenomyosis to enhance safety, effectiveness, and satisfaction during the post-pandemic era.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by qwen3.7-flash, 2026-09-10 · read from full text

This paper examines the integration of telehealth technologies with High-Intensity Focused Ultrasound (HIFU) treatments for uterine conditions following the COVID-19 pandemic. It outlines how remote communication tools can facilitate HIFU training for clinicians and support patient management for fibroids and adenomyosis by enhancing safety, effectiveness, and satisfaction. The authors propose that this hybrid model allows medical services to be delivered closer to home while maintaining clinical standards during public health crises. Relevance to endometriosis and adenomyosis: This paper is centrally about adenomyosis, specifically discussing its management via HIFU ablation supported by telehealth infrastructure.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

We come to realize the importance of “telehealth” during the current COVID-19 pandemic. Telehealth can be defined as providing health care, including preventive, diagnostic, and treatment services, by using information and communication technologies such as videoconferencing, electronic messaging, and telephone calls (1). With the rapid development of new treatment technology, communication, and fast speed networks, not only telehealth can provide medical services closer to home, but it also should provide the doctors and patients with additional benefits of safety, effectiveness, and satisfaction. HIFU is a new non-invasive ablation treatment for many solid tumors. This paper illustrates how the potential practice of HIFU ablation for fibroids can be modified to make it suitable for doctors in their HIFU training for treatment of fibroids and adenomyosis and for patients who need surgery using this new telehealth development.
Full text 1,602 characters · extracted from oa-doi-fallback · click to expand
The potential role in HIFU telehealth in the management of fibroid and adenomyosis after COVID-19 pandemic Authors/Creators - 1. School of Women's and Children's Health, The University of New South Wales, NSW, Australia. - 2. Department of Imaging and Interventional Radiology at Shanghai Xuhui District Central Hospital, Shanghai, China. - 3. State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China. Description We come to realize the importance of “telehealth” during the current COVID-19 pandemic. Telehealth can be defined as providing health care, including preventive, diagnostic, and treatment services, by using information and communication technologies such as videoconferencing, electronic messaging, and telephone calls (1). With the rapid development of new treatment technology, communication, and fast speed networks, not only telehealth can provide medical services closer to home, but it also should provide the doctors and patients with additional benefits of safety, effectiveness, and satisfaction. HIFU is a new non-invasive ablation treatment for many solid tumors. This paper illustrates how the potential practice of HIFU ablation for fibroids can be modified to make it suitable for doctors in their HIFU training for treatment of fibroids and adenomyosis and for patients who need surgery using this new telehealth development. Files WJARR-2021-0032.pdf Files (821.3 kB) | Name | Size | Download all | |---|---|---| | md5:6a1f0fd0afdce01e0938a38d102b3313 | 821.3 kB | Preview Download |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK